CA2312234A1 - Use of methylnaltrexone and related compounds - Google Patents

Use of methylnaltrexone and related compounds Download PDF

Info

Publication number
CA2312234A1
CA2312234A1 CA002312234A CA2312234A CA2312234A1 CA 2312234 A1 CA2312234 A1 CA 2312234A1 CA 002312234 A CA002312234 A CA 002312234A CA 2312234 A CA2312234 A CA 2312234A CA 2312234 A1 CA2312234 A1 CA 2312234A1
Authority
CA
Canada
Prior art keywords
opioid
methylnaltrexone
administration
induced
side effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002312234A
Other languages
French (fr)
Other versions
CA2312234C (en
Inventor
William Drell
Joseph F. Foss
Michael F. Roizen
Jonathan Moss
Chun-Su Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
UR Labs Inc
Original Assignee
Arch Development Corporation
Ur Labs, Inc.
William Drell
Joseph F. Foss
Michael F. Roizen
Jonathan Moss
Chun-Su Yuan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/962,742 external-priority patent/US5972954A/en
Application filed by Arch Development Corporation, Ur Labs, Inc., William Drell, Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan filed Critical Arch Development Corporation
Publication of CA2312234A1 publication Critical patent/CA2312234A1/en
Application granted granted Critical
Publication of CA2312234C publication Critical patent/CA2312234C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Abstract

A method for preventing or treating opioid induced side effects including dysphoria, pruritus, urinary retention and gastrointestinal dysfunction and non-opioid induced changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered by the route selected from the group consisting of intravenous, intramuscular, transmucosal, transdermal, and oral administration, preferably administered orally in an enterically coated form.
CA002312234A 1997-11-03 1998-11-03 Use of methylnaltrexone and related compounds Expired - Lifetime CA2312234C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/962,742 1997-11-03
US08/962,742 US5972954A (en) 1997-11-03 1997-11-03 Use of methylnaltrexone and related compounds
US09/120,703 1998-07-22
US09/120,703 US6274591B1 (en) 1997-11-03 1998-07-22 Use of methylnaltrexone and related compounds
PCT/US1998/023485 WO1999022737A1 (en) 1997-11-03 1998-11-03 Use of methylnaltrexone and related compounds

Publications (2)

Publication Number Publication Date
CA2312234A1 true CA2312234A1 (en) 1999-05-14
CA2312234C CA2312234C (en) 2005-03-22

Family

ID=26818669

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002312234A Expired - Lifetime CA2312234C (en) 1997-11-03 1998-11-03 Use of methylnaltrexone and related compounds

Country Status (5)

Country Link
US (6) US6274591B1 (en)
EP (1) EP1047426B1 (en)
AU (1) AU758416B2 (en)
CA (1) CA2312234C (en)
WO (1) WO1999022737A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563899B2 (en) 2005-05-25 2009-07-21 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US7674904B2 (en) 2005-05-25 2010-03-09 Progenics Pharmaceuticals, Inc. Synthesis of R-N-methylnaltrexone
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
US9492445B2 (en) 2008-09-30 2016-11-15 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662390B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9669096B2 (en) 2003-04-08 2017-06-06 Progenics Pharmaceuticals, Inc. Stable pharmaceutical formulations of methylnaltrexone
US9675602B2 (en) 2005-03-07 2017-06-13 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9717725B2 (en) 2005-03-07 2017-08-01 The University Of Chicago Use of opioid antagonists
US9879024B2 (en) 2007-03-29 2018-01-30 Progenics Pharmaceuticals., Inc. Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US10383869B2 (en) 2008-03-21 2019-08-20 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
RU2241458C2 (en) 1997-12-22 2004-12-10 Эро-Селтик, С.А. Combinations of agonist/antagonist for opioid
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1206264A2 (en) 1999-08-25 2002-05-22 Barrett R. Cooper Compositions and methods for treating opiate intolerance
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
EP1225897B1 (en) * 1999-11-01 2004-09-08 RHODES, John Composition for treatment of constipation and irritable bowel syndrome
ATE432076T1 (en) * 1999-11-29 2009-06-15 Adolor Corp NEW METHODS AND PROCEDURES FOR TREATING AND PREVENTING ILEUS
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
JP2003522144A (en) * 2000-02-08 2003-07-22 ユーロ−セルティーク，エス．エイ． Controlled release compositions comprising opioid agonists and antagonists
DE10059415A1 (en) 2000-11-30 2002-06-06 Gruenenthal Gmbh Use of weak opioids and mixed opioid agonists / antagonists for the treatment of urinary incontinence
CN1525851A (en) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ Abuse-resistant controlled-release opioid dosage form
CA2449175A1 (en) * 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
SI1416842T1 (en) 2001-07-18 2009-06-30 Euro Celtique Sa Pharmaceutical combinations of oxycodone and naloxone
ES2326794T3 (en) 2001-08-06 2009-10-20 Euro-Celtique S.A. FORMULATIONS OF OPIOID AGONISTS WITH LIBERABLE AND SEQUESTED ANTAGONISTS.
US20040259898A1 (en) * 2002-02-04 2004-12-23 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
ES2546010T3 (en) 2002-04-05 2015-09-17 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
MXPA05001826A (en) * 2002-08-15 2005-04-19 Euro Celtique Sa Pharmaceutical compositions.
CN1767855A (en) * 2003-04-08 2006-05-03 普罗热尼奇制药公司 Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
US20050004155A1 (en) * 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
CN100588391C (en) * 2003-08-12 2010-02-10 恩德制药公司 Single long acting slow-release tablet for deterring abuse of medicine
US20060194826A1 (en) * 2003-09-25 2006-08-31 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
CA2594987A1 (en) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. Therapeutic agent for constipation
US20060205753A1 (en) * 2005-01-20 2006-09-14 Israel Robert J Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
US20080027579A1 (en) * 2006-07-31 2008-01-31 Van Der Hoop Roland Gerritsen Dosage limiting medication dispensing method and apparatus
TW200815451A (en) * 2006-08-04 2008-04-01 Wyeth Corp 6-carboxy-normorphinan derivatives, synthesis and uses thereof
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
DK2139890T3 (en) 2007-03-29 2014-08-25 Wyeth Llc PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND APPLICATIONS THEREOF
WO2009009292A2 (en) * 2007-07-11 2009-01-15 Mallinckrodt Inc. Crystalline forms of naltrexone methobromide
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
JP2011500686A (en) * 2007-10-18 2011-01-06 アイコ バイオテクノロジー Combined analgesics using opioids and neutral antagonists
CN101959892B (en) 2008-02-06 2014-01-08 普罗热尼奇制药公司 Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
EP2306829B1 (en) 2008-07-01 2017-01-04 University of Chicago Particles containing a peripheral opioid receptor antagonist
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2011112816A1 (en) 2010-03-11 2011-09-15 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CA3002137A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
WO2020023486A1 (en) 2018-07-23 2020-01-30 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
CA3137488C (en) 2019-05-07 2023-10-31 Bausch Health Ireland Limited Liquid oral dosage formulations of methylnaltrexone
CA3177250A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US222911A (en) * 1879-12-23 Improvement in book-cases
US1047726A (en) * 1912-03-12 1912-12-17 Anthony J Yoggerst Pipe-cleaner.
US2625457A (en) * 1951-07-26 1953-01-13 Bernard J Baecher Course recorder
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
JPS5535031A (en) 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
US4311833A (en) 1979-03-06 1982-01-19 Daicel Chemical Industries Ltd. Process for preparing ethylcarboxymethylcellulose
US4322426A (en) * 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4377568A (en) 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (en) 1981-11-20 1987-05-25 Benzon As Alfred PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL ORAL POLYDEPOT PREPARATION
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
JPS59500418A (en) 1982-03-16 1984-03-15 ザ　ロツクフエラ−　ユニバ−シテイ How to recover from gastrointestinal dysfunction
US4457907A (en) 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4462839A (en) 1983-06-16 1984-07-31 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
JPS6229515A (en) 1985-07-30 1987-02-07 Shinjiro Tsuji Method for film-coating of hard capsule
US4861781A (en) * 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) * 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5597564A (en) 1986-08-28 1997-01-28 Enzacor Properties Limited Method of administering a microgranular preparation to the intestinal region of animals
DE3777658D1 (en) 1986-08-28 1992-04-23 Enzacor Pty Ltd ANIMAL GROWTH PATH.
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
FR2609632B1 (en) 1987-01-21 1991-03-29 Shelly Marc NOVEL THERAPEUTIC APPLICATION OF 17- (CYCLOPROPYLMETHYL) -4,5-EPOXY-3,14-DIHYDROXYMORPHINON-6-ONE AND PHARMACEUTICAL COMPOSITIONS FOR THIS USE
US4857833A (en) * 1987-08-27 1989-08-15 Teradyne, Inc. Diagnosis of faults on circuit board
CA1315689C (en) 1987-09-03 1993-04-06 Leon I. Goldberg Quarternary derivatives of noroxymorphone which relieve nausea and emesis
ES2051742T3 (en) * 1987-09-10 1994-07-01 Univ Chicago QUARTERLY DERIVATIVES OF NOROXI-MORPHINE THAT MITIGATE NAUSEA AND EMESIS.
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5102887A (en) * 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
JPH04230625A (en) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd Method for production of finely dispersed tablet composition consisting of microcapsule containing sprayed and dried sodium dichlofenac and having enteric coating
US5270328A (en) 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
ATE158180T1 (en) 1991-06-21 1997-10-15 Univ Cincinnati ORALLY ADMINISTERED THERAPEUTIC PROTEINS AND PRODUCTION METHODS
US5614219A (en) * 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
USRE36547E (en) 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5512578A (en) 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
DK0603992T4 (en) 1992-12-22 2001-03-05 Univ Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins
US5585348A (en) 1993-02-10 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5391372A (en) * 1993-06-28 1995-02-21 Campbell; Elizabeth Methods of treating colic and founder in horses
DE69503126T2 (en) * 1994-05-05 1998-11-12 Beckman Instruments Inc REPETITIVE OLIGONUCLEOTIDE MATRIX
IT1269826B (en) 1994-05-24 1997-04-15 Paolo Minoia USE OF OPTIACEAN ANTAGONISTS AND CALCIUM SALTS FOR THE PREPARATION OF MEDICATIONS FOR THE TREATMENT OF ENDORPHINE-MEDIATED PATHOLOGICAL FORMS
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5614222A (en) 1994-10-25 1997-03-25 Kaplan; Milton R. Stable aqueous drug suspensions and methods for preparation thereof
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
ES2094694B1 (en) 1995-02-01 1997-12-16 Esteve Quimica Sa NEW PHARMACEUTICALLY STABLE FORMULATION OF A COMPOUND OF BENZMIDAZOLE AND ITS PROCESS OF OBTAINING.
US6025154A (en) * 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US5804595A (en) * 1995-12-05 1998-09-08 Regents Of The University Of Minnesota Kappa opioid receptor agonists
WO1997033566A2 (en) 1996-03-12 1997-09-18 Alza Corporation Composition and dosage form comprising opioid antagonist
DE19651551C2 (en) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioid antagonist-containing galenic formulation
US6353004B1 (en) * 1997-07-14 2002-03-05 Adolor Coporation Peripherally acting anti-pruritic opiates
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6194382B1 (en) 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
EP1206264A2 (en) * 1999-08-25 2002-05-22 Barrett R. Cooper Compositions and methods for treating opiate intolerance
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
ATE432076T1 (en) 1999-11-29 2009-06-15 Adolor Corp NEW METHODS AND PROCEDURES FOR TREATING AND PREVENTING ILEUS
WO2001041705A2 (en) 1999-11-29 2001-06-14 Adolor Corporation Novel methods for the treatment and prevention of dizziness and pruritus
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
WO2001037785A2 (en) 1999-11-29 2001-05-31 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
US6967075B2 (en) * 2000-04-07 2005-11-22 Schering Corporation HCV replicase complexes
JP2004515455A (en) 2000-05-05 2004-05-27 ペイン・セラピューティクス・インコーポレイテッド Opioid antagonist compositions and dosage forms
AU7013401A (en) * 2000-06-22 2002-01-02 Univ Iowa Res Found Methods for enhancing antibody-induced cell lysis and treating cancer
CA2449175A1 (en) * 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
US7056500B2 (en) * 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
DK2368553T3 (en) * 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
CN1767855A (en) * 2003-04-08 2006-05-03 普罗热尼奇制药公司 Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
US20050004155A1 (en) * 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
WO2005041759A2 (en) * 2003-10-29 2005-05-12 Allez Physionix Ltd. Method and apparatus for determining an ultrasound fluid flow centerline
US20060205753A1 (en) * 2005-01-20 2006-09-14 Israel Robert J Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9669096B2 (en) 2003-04-08 2017-06-06 Progenics Pharmaceuticals, Inc. Stable pharmaceutical formulations of methylnaltrexone
US10376584B2 (en) 2003-04-08 2019-08-13 Progenics Pharmaceuticals, Inc. Stable pharmaceutical formulations of methylnaltrexone
US9675602B2 (en) 2005-03-07 2017-06-13 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662390B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9717725B2 (en) 2005-03-07 2017-08-01 The University Of Chicago Use of opioid antagonists
US9597327B2 (en) 2005-05-25 2017-03-21 Progenics Pharmaceuticals, Inc. Synthesis of (R)-N-methylnaltrexone
US7563899B2 (en) 2005-05-25 2009-07-21 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US7674904B2 (en) 2005-05-25 2010-03-09 Progenics Pharmaceuticals, Inc. Synthesis of R-N-methylnaltrexone
US8853232B2 (en) 2007-03-29 2014-10-07 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
US9879024B2 (en) 2007-03-29 2018-01-30 Progenics Pharmaceuticals., Inc. Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US10383869B2 (en) 2008-03-21 2019-08-20 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US9492445B2 (en) 2008-09-30 2016-11-15 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US9724343B2 (en) 2008-09-30 2017-08-08 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof

Also Published As

Publication number Publication date
EP1047426A4 (en) 2004-07-14
US20040162308A1 (en) 2004-08-19
US20020028825A1 (en) 2002-03-07
US20090312359A1 (en) 2009-12-17
US6608075B2 (en) 2003-08-19
WO1999022737A1 (en) 1999-05-14
US20030065003A1 (en) 2003-04-03
EP1047426B1 (en) 2010-05-12
US20050048117A1 (en) 2005-03-03
CA2312234C (en) 2005-03-22
US6274591B1 (en) 2001-08-14
EP1047426A1 (en) 2000-11-02
AU1380299A (en) 1999-05-24
AU758416B2 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
CA2312234A1 (en) Use of methylnaltrexone and related compounds
DE69841663D1 (en) USE OF METHYL NALTREXONE AND RELATED COMPOUNDS
WO2001093852A3 (en) Method of treating pain using nalbuphine and opioid antagonists
US4956391A (en) Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and alzheimer's disease
WO2001068080A3 (en) Neutral antagonists and use thereof in treating drug abuse
TR200103613T2 (en) Pharmaceutical formulations and methods containing morphine administered intranasally.
RU2000119779A (en) METHOD FOR PREVENTING ABUSE OF OPIOID-CONTAINING MEDICINAL FORMS
US5064858A (en) Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and Alzheimer's disease
CA2302754A1 (en) Noribogaine in the treatment of pain and drug addiction
RU2004106619A (en) COMPOSITIONS OF AN OPIOID AGONIST CONTAINING A RELEASABLE AND ISOLATED ANTAGONIST
PL331922A1 (en) Method of inhibiting fibrosis by means of an antagonist of somatotropin release inhibiting factor
CY1109264T1 (en) NEW METHODS FOR TREATMENT AND PREVENTION
WO2002013801A3 (en) Method of treating the syndrome of coronary heart disease risk factors in humans
KR970009799A (en) Treatment of substance abuse withdrawal
JPS61260025A (en) Control of abstinence syndrom by opioid-derived endurance and dependency
AU2002323873B2 (en) Active ingredient combination of E.G. galanthamine or deoxypeganine and E.G. acamprosate or memantine for treating an addiction such as alcoholism
WO2001041705A3 (en) Novel methods for the treatment and prevention of dizziness and pruritus
EP0367533A3 (en) Method of treatment for interstitial cystitis
HK1034446A1 (en) Therapeutic agents.
CA2118512A1 (en) Agents for treating substance abuse disorders
Hanks The clinical usefulness of agonist-antagonistic opioid analgesics in chronic pain
EP0799618A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer
RU2003135201A (en) APPLICATION OF THE NALTREXONE OPIOID ANTAGONIST FOR THE PREVENTION AND CONTROL OF ADVERSE EFFECTS CAUSED BY OPIOIDS
WO2002013759A3 (en) Method of treating the syndrome of type 2 diabetes in humans
GR3018335T3 (en) Use of a pure narcotic antagonist, e.g. nalmefene, naltrexone, naloxone or diprenorphine, in the treatment of mast cell disease.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20181105